Trial Profile
A Phase II study in adult patients with newly diagnosed chronic-phase chronic myeloid leukaemia of initial intensified imatinib therapy and sequential dose-escalation followed by treatment with nilotinib in suboptimal responders to determine the rate and duration of major molecular response.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms TIDEL-II
- 15 Jun 2023 Results assessing he relationship between IVKI and subsequent molecular response using samples from the TIDEL-II study and ENESTxtnd study, presented at the 28th Congress of the European Haematology Association.
- 06 Dec 2016 Results of five-year (final) analysis presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2015 Sub-study results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology